Toshiaki Kikuchi Japan

Dr. Toshiaki Kikuchi obtained his M.D. from Hokkaido University, Japan, in 1990 and his Ph.D. from Tohoku University in 1994. After completing clinical training in respirology at Tohoku Central Hospital, he began his academic career at Tohoku University, where he served in several roles including Research Assistant and Instructor. From 1997 to 2000, he was a Visiting Fellow in Pulmonary and Critical Care Medicine at Weill Medical College of Cornell University in New York, USA. He later served as Instructor in Pulmonary Medicine at Tohoku University Hospital before being appointed Professor at Niigata University Graduate School of Medical and Dental Sciences in 2015. Since 2025, he has been serving as Director of Niigata University Medical and Dental Hospital.
Job Title
Director
Faculty / Department / Division
Department of Respiratory Medicine and Infectious Diseases
Institution / Organisation
Niigata University Medical and Dental Hospital

20 November 2026, Friday

Time Session
08:30
09:00
Mycobacterial Genomics: Potential for Pulmonary NTM Disease Management
Toshiaki Kikuchi Speaker Japan
Ahmad Izuanuddin Ismail Chairperson Malaysia
Mycobacterial Genomics: Potential for Pulmonary NTM Disease Management Toshiaki Kikuchi, MD, PhD Niigata University Medical & Dental Hospital, Japan Background and Aims The incidence of pulmonary nontuberculous mycobacterial (NTM) disease is increasing worldwide, particularly in Japan, where Mycobacterium avium complex predominates. Some patients experience disease progression that requires antimicrobial treatment, whereas others remain stable without treatment for years. Because disease progression is difficult to predict, deciding when to start treatment remains challenging. We investigated whether the genomic characteristics of M. avium clinical isolates are associated with disease progression. Methods We performed whole-genome sequencing of 36 clinical M. avium isolates from patients with progressive (n = 25) or stable (n = 11) disease. Progressive disease was defined as initiation of treatment within 12 months of diagnosis, and stable disease as no treatment during this period. Comparative analyses included whole-genome alignment, phylogenetic analysis based on average amino acid identity (AAI), and single-nucleotide variant (SNV) analysis. Results Comparative genomic analysis identified a 1.4-Mb genomic inversion that distinguished two genomic types, type A and type non-A. All 15 type A isolates were from patients with progressive disease, whereas the 21 type non-A isolates were from patients with progressive (n = 10) or stable (n = 11) disease. Type A isolates also lacked genes adjacent to the inversion breakpoints, including the vapBC-5 toxin–antitoxin system, which may affect the regulation of bacterial growth. AAI-based phylogenetic analysis independently separated type A from type non-A isolates and revealed additional clusters associated with disease progression. Furthermore, SNV analysis of type non-A isolates identified variants associated with progression, including one in uvrB, a gene involved in DNA repair. Conclusion These findings suggest that genomic profiling of M. avium isolates may help predict disease progression and guide individualized treatment decisions in pulmonary NTM disease. Keywords: Nontuberculous mycobacteria, Whole-genome sequencing, Disease progression Reference: Tanaka K et al, Int J Infect Dis, 2026, 169, 108816. Disclosure Statement: The presenting author has received honoraria or consultation fees from Insmed, KYORIN Pharmaceutical, and Janssen Pharmaceutical.
Ballroom 3, Lower Ground Floor

22 November 2026, Sunday

Time Session
11:00
12:00
David Lam Chi-Leung Chairperson Hong Kong
Toshiaki Kikuchi Chairperson Japan
  • Toshiaki Kikuchi Speaker Japan
    Publishing in Respirology: What are the Editors Looking For? Toshiaki Kikuchi, MD, PhD Niigata University Medical & Dental Hospital, Japan This presentation provides an overview of recent developments at Respirology, including changes in editorial leadership and the expansion of the editorial team to accommodate a growing number of manuscript submissions. Throughout these changes, the journal has maintained consistent editorial standards. The role of initial editorial screening in ensuring an efficient and rigorous peer review process will also be discussed. Particular emphasis will be placed on five key criteria that editors consider when evaluating manuscripts: novelty, methodological rigour, clinical relevance, generalisability, and relevance to a broad readership. Successful manuscripts should provide meaningful advances beyond existing knowledge, employ robust study designs with appropriate control for confounding, and demonstrate clear clinical or translational implications. Findings should also be applicable across diverse clinical settings and countries, rather than limited to highly specific local circumstances. Importantly, manuscripts should address questions of interest to a broad international respiratory readership. The presentation will also highlight Respirology’s recent impact factor trends and its commitment to publishing high-quality research of interest to a wide range of respiratory clinicians across the Asia-Pacific region and beyond. By clarifying editorial expectations, this session aims to help researchers prepare stronger manuscripts and to encourage their active participation in the peer review process. Keywords: Editorial process, Peer review, Editorial policies Disclosure Statement: The presenting author has received honoraria or consultation fees from Insmed, KYORIN Pharmaceutical, and Janssen Pharmaceutical.
  • Keiko Kan-O Speaker Japan
  • Alison Bell Speaker Australia
  • Q&A
Ballroom 1, Lower Ground Floor